When a Negative Allergy Test Does Not Rule Out Allergy
Medicine diagnoses patients—not laboratory values.
A mother brings her 13-year-old child to clinic because she is frustrated.
For years, she has watched her child wake most mornings sneezing, rubbing an itchy nose and struggling with nasal congestion. The symptoms are worse in the bedroom and on waking. Changing the bed linen, cleaning a dusty room or sleeping away from home affects them predictably.
The child also looks allergic. The nasal lining is pale and swollen, with oedema and early tissue remodelling around the middle turbinate—the area where inhaled allergens commonly contact the central nasal airway.
Yet the family has been told that the child does not have an allergy.
A skin-prick test was negative. A blood test for allergen-specific immunoglobulin E, or IgE, was also negative. These results were interpreted as though their negative predictive value were 100%:
Negative test equals no allergy.
For the parent, years of observing a consistent pattern appear to count for nothing. More importantly, the negative tests close the treatment pathway. Further assessment stops, and disease-modifying treatment such as allergen immunotherapy may never be considered.
The mistake was not performing the tests.
The mistake was asking those tests to provide certainty that they cannot provide.
A negative systemic allergy test is useful evidence. It is not proof that allergen-driven disease is absent from the respiratory mucosa.
Medicine diagnoses patients—not laboratory values
Modern medicine increasingly depends on biomarkers, imaging and laboratory investigations. These tools improve diagnosis, but they do not replace a fundamental principle:
Diseases occur in patients—not in laboratory reports.
Medicine usually reduces uncertainty rather than eliminating it. Every new piece of information changes the probability of a diagnosis. Few investigations prove or disprove disease in isolation.
This is Bayesian clinical reasoning.
A classic history of sneezing, itching, watery discharge and congestion increases the probability of allergic rhinitis. Symptoms that reliably worsen in the bedroom or on waking increase the probability of house dust-mite allergy. A characteristic nasal examination increases it further.
A negative skin or blood test then reduces that probability—but does not necessarily reduce it to zero.
Evidence-based medicine was never intended to replace clinical judgement. It was intended to make clinical judgement better informed.
What do conventional allergy tests measure?
A skin-prick test measures cutaneous sensitisation. It asks whether allergen-specific IgE attached to mast cells in the skin can produce a wheal-and-flare response.
A serum-specific IgE assay measures circulating allergen-specific IgE in the bloodstream.
Neither directly measures the entire allergic response occurring within the nasal or lower-airway mucosa—the tissues actually producing the patient’s respiratory symptoms.
Allergen-specific IgE may be produced locally within the nasal mucosa, bind to resident mast cells and contribute to inflammation without being adequately represented in the blood or skin.
A negative systemic test therefore reduces the probability of systemic sensitisation. It does not completely exclude clinically important nasal allergy.
Skin and blood allergy tests assess systemic sensitisation but may not detect an allergic response confined to the nasal mucosa.
Skin-prick testing assesses allergen reactivity in the skin. It does not directly test the immune response occurring within the respiratory mucosa.
How do tests for nasal inhalant allergy compare?
The studies below used different allergens, populations, thresholds and reference standards. The figures should therefore be interpreted as practical summaries rather than direct head-to-head comparisons.
Test or finding What it assesses Summary of published performance Clinical meaning Skin-prick testing Cutaneous IgE sensitisation Pooled sensitivity 85%, specificity 77%, approximate LR+ 3.7 and LR− 0.19. Useful, but sensitivity is not 100%. A negative test cannot completely exclude nasal allergy. Serum allergen-specific IgE Circulating allergen-specific IgE No universal figures. Performance varies by allergen, component, assay and threshold. Helpful when positive and clinically relevant, but may miss predominantly local nasal IgE. Middle turbinate oedema Visible inflammatory remodelling in the nose Multifocal or greater oedema: sensitivity 23.4%, specificity 94.7%, PPV 85.1%, LR+ 4.39. Diffuse or greater oedema: sensitivity 12.9%, specificity 98.5%, PPV 91.7%, LR+ 8.60. Strong positive evidence when present, but absence does not exclude allergy. Nasal allergen provocation Allergen-specific response within the nasal target organ Positive in 86.3% of patients classified as allergic systemically and 24.7% of those classified as non-allergic. Positive responses among allergic patients were 97.1% for pollen and 79.1% for dust. The closest available gold standard for clinically relevant nasal allergy. Results depend on testing the correct allergen and defining a positive response appropriately.
The pooled skin-prick figures are from a systematic review using nasal provocation or clinical diagnosis as reference standards.
Nasal allergen provocation tests the target organ
During nasal allergen provocation, a suspected allergen is applied directly to the nasal mucosa. The response is assessed using symptoms and objective measures such as nasal airflow, rhinomanometry or nasal peak inspiratory flow.
Unlike skin or blood testing, nasal provocation asks the clinically important question:
Does this allergen produce an allergic response in this patient’s nose?
It is therefore the closest available gold standard for clinically relevant nasal allergy and local allergic rhinitis.
The procedure does have practical limitations. Only one allergen can generally be tested during a challenge session. A negative response may mean that the wrong allergen was selected. Results also depend on allergen dose, medication use, baseline nasal reactivity and the criteria used to define a positive response.
The systematic review by Hamizan and colleagues found that positive results varied according to the allergen and whether symptoms, objective measurements or both were required. This reflects the practical complexity of nasal challenge rather than diminishing its value as a target-organ test.
Local allergic rhinitis explains some negative tests
Some patients previously labelled as having non-allergic rhinitis have a local IgE-mediated response confined predominantly to the nose. This is called local allergic rhinitis, or entopy.
A systematic review led by Aneeza Hamizan found that approximately one-quarter of patients with rhinitis but negative systemic allergy tests still developed a positive response when an allergen was applied directly to the nasal mucosa.
A second systematic review found nasal-specific IgE in 10.2% of patients classified as having non-allergic rhinitis. Among patients whose clinical history remained suggestive of allergy, the proportion was approximately 19.8%, compared with essentially none of those without an allergy-like history.
The history was not background noise. It identified the patients most likely to have local allergy missed by systemic testing.
The nose may contain evidence that the blood misses
Our research group subsequently measured allergen-specific IgE directly within inferior turbinate tissue.
Using a tissue-specific IgE threshold above 0.10 kUA/L, turbinate tissue testing had an area under the receiver-operating curve of 0.87, with 90% sensitivity and an 89% negative predictive value for allergic rhinitis.
Turbinate biopsy is too invasive to become a routine allergy test. Its importance is biological:
Allergen-specific IgE can be present within the target organ without being adequately represented in the blood or skin.
Aneeza Hamizan and colleagues also demonstrated that nasal brushing could collect nasal-specific IgE and compare well with inferior turbinate tissue biopsy. Although still largely a research tool, nasal brushing provides further evidence that the immune environment inside the nose cannot always be inferred from systemic tests.
For a broader explanation of inflammation and airflow within the nose, see nasal congestion is not always the same as nasal obstruction.
Middle turbinate oedema is strong positive evidence
One useful endoscopic finding is oedema affecting the head of the middle turbinate.
Multifocal, diffuse or polypoid middle turbinate oedema is highly specific for inhalant allergen sensitisation, although it has low sensitivity.
The practical rule is straightforward:
Pronounced middle turbinate oedema supports inhalant allergy. A normal middle turbinate does not exclude it.
In the Hamizan study, dust was the most frequent sensitisation, occurring in 82.1% of allergen-sensitised patients.
Middle turbinate oedema does not prove which allergen is responsible. However, established tissue remodelling suggests repeated exposure. When it occurs with perennial symptoms that are worse in the bedroom or on waking, house dust mite becomes a particularly coherent explanation.
The middle turbinate mucosal remodelling is well described in allergy and does change with disease modification (as seen here after immunotherapy)
Middle turbinate oedema has low sensitivity but high specificity for inhalant allergen sensitisation. Its presence is meaningful; its absence does not exclude allergy.
Central compartment atopic disease demonstrates the limits of biomarkers
The same principle becomes particularly important in central compartment atopic disease, or CCAD.
CCAD causes oedema and polypoid remodelling of central nasal structures, particularly the middle turbinate, superior turbinate and posterosuperior septum.
In our comparison of CCAD with classic eosinophilic chronic rhinosinusitis, the groups were clinically distinct. Patients with CCAD were younger, more likely to have early-onset asthma, more likely to experience barotrauma and less likely to have prominent smell loss or synchronously active lower-airway disease.
Despite these differences, systemic IgE measurements did not reliably separate the two phenotypes.
A separate study found that central-compartment-type CRS was associated with tissue eosinophilia and increased IL-5 and IL-13 within middle turbinate tissue, while systemic allergen sensitisation did not significantly distinguish it from other CRS phenotypes.
The lesson is broader than allergy:
Failure of a systemic biomarker to distinguish two diseases does not prove that the diseases are biologically the same.
Practical approach when the tests and the patient disagree
When the clinical phenotype strongly supports house dust-mite allergy:
Negative skin and serum tests should not automatically end the diagnostic process. Middle turbinate oedema and central tissue remodelling usually suggest repeated perennial exposure (suchg as HDM), particularly when symptoms are worse in the bedroom or on waking. Nasal allergen provocation remains the closest available gold standard, but it is time-consuming and is not routinely performed in our practice. A six-month trial of immunotherpay provides an early opportunity to assess tolerability and clinical response before moving towards less reversible treatments such as surgery. A clear local allergic response to the initial sublingual dust-mite tablet can provide strong additional clinical support, particularly when it matches the history and nasal phenotype. This remains a clinical observation rather than a formally validated diagnostic test. Six months is only an early review point. The full disease-modifying benefit of immunotherapy generally requires a longer treatment course but clinical response should be obvious by 6mths)
For further discussion of why anatomical findings should not automatically lead to surgery, see a septal deviation or “big turbinates” is not a diagnosis
Conclusion
A negative allergy test is evidence, but it is not a verdict.
Skin-prick testing examines cutaneous sensitisation. Serum testing measures circulating allergen-specific IgE. Neither directly measures the complete allergic response occurring within the respiratory mucosa.
Local allergen reactivity, nasal-specific IgE, middle turbinate oedema and the phenotype of central compartment atopic disease all demonstrate that the biology inside the nose may not be fully represented by testing elsewhere.
Bayesian reasoning provides the appropriate framework. Every finding changes probability. No single result should automatically erase the evidence supplied by the history, examination and behaviour of the disease over time.
Most clinical decisions are made with incomplete information. The clinician’s responsibility is to recognise that uncertainty, explain it clearly and decide whether the available evidence is sufficient to move the patient safely towards treatment.
Ultimately, medicine diagnoses patients—not laboratory values.
References
Nevis IF, Binkley K, Kabali C. Diagnostic accuracy of skin-prick testing for allergic rhinitis: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2016;12:20. Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. Saricilar EC, Hamizan A, Alvarado R, et al. Optimizing protein harvest from nasal brushings for determining local allergy responses. Am J Rhinol Allergy. 2018;32(4):244–251. Hamizan AW, Rimmer J, Alvarado R, et al. Turbinate-specific IgE in normal and rhinitic patients. Am J Rhinol Allergy. 2019;33(2):178–183. Hamizan AW, Christensen JM, Ebenzer J, et al. Middle turbinate edema as a diagnostic marker of inhalant allergy. Int Forum Allergy Rhinol. 2017;7(1):37–42. Hamizan AW, Christensen JM, Ebenezer J, et al. Response to: Defining a diagnostic marker: a pragmatic requirement. Int Forum Allergy Rhinol. 2017;7(6):634–635. Hamizan AW, Rimmer J, Alvarado R, et al. Positive allergen reaction in allergic and nonallergic rhinitis: a systematic review. Int Forum Allergy Rhinol. 2017;7(9):868–877. Hamizan AW, Rimmer J, Husain S, et al. Local specific immunoglobulin E among patients with non-allergic rhinitis: a systematic review. Rhinology. 2019;57(1):10–20. Hamizan AW, Rimmer J, Alvarado R, et al. Turbinate-specific IgE in normal and rhinitic patients. Am J Rhinol Allergy. 2019;33(2):178–183. Hamizan A, Alvarado R, Rimmer J, et al. Nasal mucosal brushing as a diagnostic method for allergic rhinitis. *Allergy Asthma Proc
Frequently asked questions
Can someone have allergic rhinitis despite negative skin and blood tests?
Yes. Skin-prick testing assesses allergen sensitisation in the skin, while serum-specific IgE testing measures circulating antibodies. Some patients have a local allergic response within the nasal mucosa despite negative systemic tests. This is known as local allergic rhinitis.
What is local allergic rhinitis?
Local allergic rhinitis is an allergen-driven response within the nose that occurs despite negative conventional skin-prick and serum-specific IgE tests. The diagnosis can be supported by nasal allergen provocation or detection of allergen-specific IgE within nasal secretions or tissue.
Is nasal allergen provocation the gold standard for nasal allergy?
Nasal allergen provocation is the closest available gold standard because it tests the target organ directly. A selected allergen is applied to the nasal mucosa and the resulting symptoms and physiological response are measured. A negative result may occur if the wrong allergen is selected or the criteria for a positive response are too restrictive.
What does middle turbinate oedema indicate?
Multifocal, diffuse or polypoid middle turbinate oedema is highly specific for inhalant allergen sensitisation. Its presence provides strong supportive evidence of allergy, but its low sensitivity means that a normal middle turbinate cannot exclude allergic disease.
Can dust mite immunotherapy be considered when conventional tests are negative?
In carefully selected patients, yes. A monitored trial may be reasonable when there are perennial symptoms, a strong bedroom or morning association, characteristic nasal inflammation and no more convincing alternative diagnosis. The uncertainty, risks, costs and alternatives should be discussed before treatment begins.
How long should a trial of dust mite immunotherapy continue before review?
Six months is a reasonable early review point for tolerability, adherence and an initial clinical response. It is not the full treatment course, and the longer-term disease-modifying effects of immunotherapy generally require treatment over several years.
